247 related articles for article (PubMed ID: 7542114)
21. The clinical utility of granulocyte colony-stimulating factor: early achievements and future promise.
Morstyn G; Foote M; Perkins D; Vincent M
Stem Cells; 1994; 12 Suppl 1():213-27; discussion 227-8. PubMed ID: 7535147
[TBL] [Abstract][Full Text] [Related]
22. Economic implications of using pegfilgrastim rather than conventional G-CSF to prevent neutropenia during small-cell lung cancer chemotherapy.
Tan Sean P; Chouaid C; Hettler D; Baud M; Hejblum G; Tilleul P
Curr Med Res Opin; 2009 Jun; 25(6):1455-60. PubMed ID: 19419340
[TBL] [Abstract][Full Text] [Related]
23. A retrospective study of patients' out-of-pocket costs for granulocyte colony-stimulating factors.
Tomic K; Long S; Li X; Fu AC; Yu TC; Barron R
J Oncol Pharm Pract; 2013 Dec; 19(4):328-37. PubMed ID: 23353712
[TBL] [Abstract][Full Text] [Related]
24. The use and effectiveness of granulocyte colony-stimulating factor in primary prophylaxis for febrile neutropenia in the outpatient setting.
Tuffaha HW; Treish IM; Zaru L
J Oncol Pharm Pract; 2008 Sep; 14(3):131-8. PubMed ID: 18524866
[TBL] [Abstract][Full Text] [Related]
25. [The efficacy of G-CSF and GM-CSF in the adjunctive treatment of infections complicating chemotherapy of solid tumors in children. Report of Polish Pediatric Leukemia/Lymphoma Treatment Group].
Chybicka A; Bogusławska-Jaworska J; Rosińska B; Wecławek-Tompol J; Armata J; Balcerska A; Balwierz W; Bubała H; Drabko K; Eliasińska A; Kedziora M; Kołecki P; Kowalczyk J; Matysiak M; Płoszyńska A; Rokicka-Milewska R; Sońta-Jakimczyk D; Sopyło B; Stefaniak MJ; Stańczak E; Stencel D; Wysocki M
Wiad Lek; 1998; 51 Suppl 4():65-71. PubMed ID: 10731946
[TBL] [Abstract][Full Text] [Related]
26. [The effectiveness of G-CSF and GM-CSF in the adjunctive treatment of infections complicating chemotherapy of non-Hodgkin's lymphoma in children. Report of Polish Pediatric Leukemia/Lymphoma Treatment Group].
Chybicka A; Bogusławska-Jaworska J; Rosińska B; Wecławek-Tompol J; Armata J; Balcerska A; Balwierz W; Bubała H; Drabko K; Eliasińska A; Kedziora M; Sońta-Jakimczyk D; Sopyło B; Kołecki P; Kowalczyk J; Matysiak M; Rokicka-Milewska R; Stefaniak MJ; Stańczak E; Stencel D; Wysocki M; Płoszyńska A
Wiad Lek; 1998; 51 Suppl 4():72-8. PubMed ID: 10731947
[TBL] [Abstract][Full Text] [Related]
27. Review of granulocyte colony-stimulating factors in the treatment of established febrile neutropenia.
Pérez Velasco R
J Oncol Pharm Pract; 2011 Sep; 17(3):225-32. PubMed ID: 20562168
[TBL] [Abstract][Full Text] [Related]
28. [Granulocyte colony-stimulating factor in the treatment of febrile neutropenia].
López-Hernández MA; Jiménez-Alvarado R; Borbolla-Escoboza R; de Diego Flores-Chapa J; Alvarado-Ibarra M; González-Avante M; Trueba-Chrysti ME; Anaya-Cuéllar I
Gac Med Mex; 2000; 136(2):99-105. PubMed ID: 10815320
[TBL] [Abstract][Full Text] [Related]
29. A case-control retrospective study of the efficacy of granulocyte-colony-stimulating factor in children with neuroblastoma.
Housholder SE; Rackoff WR; Goldman J; Breitfeld PP
Am J Pediatr Hematol Oncol; 1994 May; 16(2):132-7. PubMed ID: 7513135
[TBL] [Abstract][Full Text] [Related]
30. Prospective randomized trial to evaluate two delayed granulocyte colony stimulating factor administration schedules after high-dose cytarabine therapy in adult patients with acute lymphoblastic leukemia.
Hofmann WK; Seipelt G; Langenhan S; Reutzel R; Schott D; Schoeffski O; Illiger HJ; Hartmann F; Balleisen L; Franke A; Fiedler F; Huber C; Rasche H; Bergmann L; Ganser A; Pott C; Pasold R; Rudolph C; Ottmann OG; Gökbuget N; Hoelzer D
Ann Hematol; 2002 Oct; 81(10):570-4. PubMed ID: 12424538
[TBL] [Abstract][Full Text] [Related]
31. A prospective randomized trial of thymopentin versus granulocyte--colony stimulating factor with or without thymopentin in the prevention of febrile episodes in cancer patients undergoing highly cytotoxic chemotherapy.
Gebbia V; Valenza R; Testa A; Cannata G; Borsellino N; Gebbia N
Anticancer Res; 1994; 14(2B):731-4. PubMed ID: 7516641
[TBL] [Abstract][Full Text] [Related]
32. Health care outcomes case study: Febrile neutropenia.
Holdsworth MT; Duncan MH
Am J Health Syst Pharm; 1995 Oct; 52(19 Suppl 4):S15-8. PubMed ID: 8846241
[TBL] [Abstract][Full Text] [Related]
33. Cost effectiveness of primary pegfilgrastim prophylaxis in patients with breast cancer at risk of febrile neutropenia.
Aarts MJ; Grutters JP; Peters FP; Mandigers CM; Dercksen MW; Stouthard JM; Nortier HJ; van Laarhoven HW; van Warmerdam LJ; van de Wouw AJ; Jacobs EM; Mattijssen V; van der Rijt CC; Smilde TJ; van der Velden AW; Temizkan M; Batman E; Muller EW; van Gastel SM; Joore MA; Borm GF; Tjan-Heijnen VC
J Clin Oncol; 2013 Dec; 31(34):4283-9. PubMed ID: 24166522
[TBL] [Abstract][Full Text] [Related]
34. Granulocyte colony-stimulating factor in severe chemotherapy-induced afebrile neutropenia.
Hartmann LC; Tschetter LK; Habermann TM; Ebbert LP; Johnson PS; Mailliard JA; Levitt R; Suman VJ; Witzig TE; Wieand HS; Miller LL; Moertel CG
N Engl J Med; 1997 Jun; 336(25):1776-80. PubMed ID: 9187067
[TBL] [Abstract][Full Text] [Related]
35. [Economic evaluation of prophylaxis with recombinant granulopoiesis stimulating factor].
Antoñanzas F; Rovira J; Garuz R; Antón F
Med Clin (Barc); 1992 Nov; 99(18):685-9. PubMed ID: 1282638
[TBL] [Abstract][Full Text] [Related]
36. [Clinical evaluation of recombinant human G-CSF in children with cancer].
Tsukimoto I; Hanawa Y; Takaku F; Asano S; Ueda K; Tsuchida M; Sato T; Ohira M; Hoshi Y; Nishihira K
Rinsho Ketsueki; 1990 Oct; 31(10):1647-55. PubMed ID: 1701501
[TBL] [Abstract][Full Text] [Related]
37. Comparative cost-efficiency across the European G5 countries of various regimens of filgrastim, biosimilar filgrastim, and pegfilgrastim to reduce the incidence of chemotherapy-induced febrile neutropenia.
Aapro M; Cornes P; Abraham I
J Oncol Pharm Pract; 2012 Jun; 18(2):171-9. PubMed ID: 21610020
[TBL] [Abstract][Full Text] [Related]
38. [The effect of recombinant human granulocyte colony-stimulating factor (rG-CSF) on childhood neutropenias].
Ueda K; Hanawa Y; Takaku F; Asano S; Tsukimoto I; Tsuchida M; Sato T; Ohira M; Hoshi Y; Nishihira K
Rinsho Ketsueki; 1991 Mar; 32(3):212-20. PubMed ID: 1710294
[TBL] [Abstract][Full Text] [Related]
39. Peg-filgrastim and cabazitaxel in prostate cancer patients.
Di Lorenzo G; DʼAniello C; Buonerba C; Federico P; Rescigno P; Puglia L; Ferro M; Bosso D; Cavaliere C; Palmieri G; Sonpavde G; De Placido S
Anticancer Drugs; 2013 Jan; 24(1):84-9. PubMed ID: 23044721
[TBL] [Abstract][Full Text] [Related]
40. Granulocyte colony-stimulating factor in the treatment of high-risk febrile neutropenia: a multicenter randomized trial.
García-Carbonero R; Mayordomo JI; Tornamira MV; López-Brea M; Rueda A; Guillem V; Arcediano A; Yubero A; Ribera F; Gómez C; Trés A; Pérez-Gracia JL; Lumbreras C; Hornedo J; Cortés-Funes H; Paz-Ares L
J Natl Cancer Inst; 2001 Jan; 93(1):31-8. PubMed ID: 11136839
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
